2026.01.08 微信编辑| 七三 1月7日，毛戈平公司的股价盘中上涨达到5.3%, 当日开盘价为81.75港元，最高飙升至88.900港元。按这 样的股价范围，这六名控股股东和执行董事最少能套现14亿港元。 第一财经持续追踪财经热点。若您掌握公司动态、行业趋势、金融事件等有价值的线索，欢迎提供。专 用邮箱：bianjibu@yicai.com 公告显示，本次减持的人员除了毛戈平、汪立群夫妇，还包括执行董事毛霓萍、毛慧萍、汪立华及宋虹 佺。据了解，前两位是毛戈平的姐姐，汪立华为汪立群的弟弟，宋虹佺为公司核心高管。 对于这次减持的目的，公告显示，公司股东系因自身财务需求拟减持其所持有的部分股份，减持所得款 项用途包括但不限于美妆相关产业链的投资、改善个人生活等。同时，公告强调，控股股东及董事对公 司发展充满信心，将持续致力于公司的产品研发及生产经营管理。另外，本次股份减持计划的实施不会 导致本公司控制权发生变更，不会对本公司治理结构和持续经营产生重大影响。 据悉，毛戈平于2024年10月在港交所上市，上市时头顶"港股国货彩妆第一股"光环，之后，其股价表现 一直不俗，当时的发行价为29.8港元，开盘价达到47 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The report highlights that the reduction in shareholding by major shareholders has been completed, which is expected to contribute to the creation of a high-end luxury beauty ecosystem [5] - The company has signed a strategic cooperation framework agreement with L Catterton Asia Advisors to assist in global market expansion, acquisitions, and strategic investments [8] - The company's strong sales performance in both online and offline channels supports the positive outlook for its future profitability [8] Financial Performance and Forecast - Revenue projections for the company are as follows: - 2023: 2,885.96 million RMB - 2024: 3,884.69 million RMB (growth of 34.61%) - 2025: 5,153.06 million RMB (growth of 32.65%) - 2026: 6,608.46 million RMB (growth of 28.24%) - 2027: 8,340.36 million RMB (growth of 26.21%) [7] - Net profit forecasts are: - 2023: 661.9 million RMB - 2024: 880.6 million RMB (growth of 33.0%) - 2025: 1,212.7 million RMB (growth of 37.7%) - 2026: 1,580.4 million RMB (growth of 30.3%) - 2027: 2,030.8 million RMB (growth of 28.5%) [7] - Earnings per share (EPS) estimates are: - 2023: 3.31 RMB - 2024: 2.18 RMB - 2025: 2.47 RMB - 2026: 3.22 RMB - 2027: 4.14 RMB [7] Strategic Developments - The company plans to utilize the proceeds from the share reduction for investments in the beauty-related industry and personal improvements [8] - The collaboration with L Catterton aims to leverage their global investment network to enhance the company's brand presence in high-end retail channels [8]

Core Viewpoint - The article discusses the share reduction announcement by Mao Geping Cosmetics Co., Ltd., highlighting the planned sale of up to 17.2 million H-shares by major shareholders, including the founders, for personal financial needs while expressing confidence in the company's future [3][4]. Group 1 - Mao Geping announced a share reduction plan involving six major shareholders, including the founders, intending to sell up to 17.2 million H-shares, which is 3.51% of the total issued shares [3]. - Following the announcement, the company's stock price rose by 5.3%, with a trading range between 81.75 HKD and 88.90 HKD, potentially allowing the shareholders to cash out at least 1.4 billion HKD [3]. - The purpose of the share reduction is attributed to personal financial needs, with proceeds intended for investments in the beauty industry and personal lifestyle improvements [3]. Group 2 - Mao Geping was listed on the Hong Kong Stock Exchange in October 2024, initially priced at 29.8 HKD, with the opening price reaching 47.65 HKD, indicating nearly a twofold increase in stock price since then [4]. - The timing of the share reduction coincides with the first window of opportunity following the expiration of the 12-month lock-up period for major shareholders and executives [5].

Core Viewpoint - The announcement from Mao Geping Cosmetics Co., Ltd. indicates that six major shareholders, including the founders, plan to reduce their holdings by up to 17.2 million H-shares, representing 3.51% of the total issued shares, primarily through block trades within six months [1][5]. Group 1: Shareholder Reduction Details - The shareholders involved in the reduction include founders Mao Geping and Wang Liqun, as well as directors Mao Nipin, Mao Huiping, Wang Lihua, and Song Hongqian [3]. - The estimated cash-out from this reduction could be at least HKD 1.4 billion based on the opening price of HKD 81.75, and up to HKD 1.53 billion at the peak price of HKD 88.9 [5]. Group 2: Purpose and Impact of the Reduction - The reduction is driven by personal financial needs, with proceeds intended for investments in the beauty industry and personal living improvements. The announcement reassures that this will not affect the company's control or governance structure [5][6]. - The timing of the reduction coincides with the first window after the lock-up period, which typically lasts for 12 months post-IPO [5]. Group 3: Market Reaction and Performance - Following the announcement, the stock price of Mao Geping rose by 5.3%, reaching a peak of HKD 88.9, with a closing price of HKD 87.95, reflecting a 7.26% increase [1][8]. - Citigroup's report suggests that the potential reduction could exert short-term pressure on the stock price, but maintains a "buy" rating with a target price of HKD 82, citing strong earnings growth prospects [6][7]. Group 4: Financial Performance - For the first half of 2025, Mao Geping reported revenue of HKD 2.588 billion, a year-on-year increase of 31.3%, and a net profit of HKD 670 million, up 36.1% [7]. - The gross margin for the same period was 84.2%, slightly down from 84.9% year-on-year, indicating robust profitability despite a minor decline in margin [7].

Core Insights - The mascara market in China has evolved from a "non-essential" product to a "daily necessity," driven by the younger generation's demand for natural, long-lasting, and multifunctional makeup effects [1][11] - In 2024, the total sales of mascara in China are projected to reach 2.004 billion yuan, with high-end mascara accounting for approximately 25.0% and mass-market mascara for about 74.9% [1][11] - The trend towards clean beauty and sensitivity-friendly products is pushing companies to accelerate the development of low-sensitivity, nourishing, and multifunctional mascara products [1][11] Overview - Mascara is defined as a viscous product made from a mixture of oils, water, wax, thickeners, pigments, film-forming agents, and emulsifiers, primarily used to enhance and beautify eyelashes [2] Development History - The mascara industry in China has undergone four major stages: introduction of imported products, rapid popularization, innovation and differentiation, and compliance with high-quality standards [5] - Domestic brands have shifted from imitation to breakthroughs in technology and branding, narrowing the gap with international brands [5][6] Market Policies - The Chinese government has implemented various regulations to enhance the quality and safety of cosmetics, including mascara, promoting a shift towards standardized and high-quality production [6][7] Industry Chain - The mascara industry supply chain includes raw material suppliers (oils, waxes, pigments), component suppliers (brush heads, tubes), and sales channels (department stores, beauty shops, e-commerce) [7][8] Consumer Insights - The primary consumer demographic for mascara in China is women, making up 90.3% of the market, with the age group of 18-35 years accounting for 78.6% of consumers [9][10] - Over 80% of consumers prioritize waterproof and smudge-proof features, while 40% consider ease of application as a key factor influencing repurchase rates [9][10] Competitive Landscape - The mascara market is highly competitive, featuring both international brands (e.g., Yves Saint Laurent, Lancôme, Dior) and domestic brands (e.g., Maogeping, CarziLan, Huaxizi) [11][12] - Domestic brands are leveraging insights into Asian consumer preferences and innovative marketing strategies to capture market share [11][12] Development Trends - There is a shift towards multifunctional and natural ingredient-based mascara products, with an emphasis on nurturing properties and reduced irritants [14] - Online sales channels are expected to strengthen, with innovations in marketing strategies such as social e-commerce and live streaming [15] - The rise of domestic brands is supported by the growing trend of national pride, with brands incorporating traditional cultural elements into their products [16]

转自：劳动午报 当你在网络平台搜索"个性穿孔"，琳琅满目的工作室广告瞬间弹出，包括舌钉、唇钉、脐钉等不同项 目；当你在商场选购化妆品，却发现不少商品缺少明确的生产信息，标签内容模糊不清；当你路过美容 店，随手接过的宣传单上竟写着"皮肤管理可治疗抑郁症"……如今，人们对美的追求日益多元，美容项 目层出不穷，但这些服务背后，是否藏着不为人知的风险？近年来，贵州省贵阳市检察机关积极履行公 益诉讼检察职责，聚焦医疗美容和化妆品等领域开展法律监督，切实守护人民群众的"颜值安全"。（1 月1日《法治日报》） （来源：劳动午报） □邰怡明 ...

1月7日，毛戈平公司的股价盘中上涨达到5.3%,当日开盘价为81.75港元，最高飙升至88.900港元。按这样的 股价范围，这六名控股股东和执行董事最少能套现14亿港元。 创始人夫妇及其姐弟集体减持 公告显示，本次减持的人员除了毛戈平、汪立群夫妇，还包括执行董事毛霓萍、毛慧萍、汪立华及宋虹 佺。据了解，前两位是毛戈平的姐姐，汪立华为汪立群的弟弟，宋虹佺为公司核心高管。 毛戈平、汪立群夫妇 公告表示，这次六人合计减持其所持有的公司H股股份数量不超过1720万股，即不超过本公司已发行股份 总数的3.51%。南都记者以1月7日开盘价81.75港元计算，这次减持六人共计可以套现最少14亿元，若按截 至发稿之时的最高估价88.9港元来计算，则共计能套现15.3亿港元。 1月6日晚，毛戈平化妆品股份有限公司(以下简称"毛戈平")发布股份减持公告。公告显示，包含创始人夫 妇毛戈平和汪立群在内的六位公司控股股东和执行董事拟自公告披露之日起6个月内主要通过大宗交易方 式合计减持其所持有的公司H股股份数量不超过1720万股，即不超过本公司已发行股份总数的3.51%。 花旗发表的研究报告显示，毛戈平潜在减持股数最高占H股股本6.6 ...

（原标题：韩国全年出口额突破7000亿美元大关） 产通部分析称，此次新高反映出韩国出口结构越发多元化特征。以半导体为首的电子产业以及汽 车、船舶、生物医药等传统主力产业继续保持强势，与此同时，韩流文化带动食品、化妆品等消费品成 为新的增长动力。 据韩联社12月29日报道，韩产业通商资源部与关税厅29日发布统计显示，韩国今年全年累计出口额 首次突破7千亿美元大关，达到历史新高。这一成绩使韩国在全球出口国家中位列第六。过去重要里程 碑包括1995年、2004年、2006年、2008年、2011年和2018年分别突破1千亿美元、2千亿美元、3千亿美 元、4千亿美元和6千亿美元等关口。本次突破7千亿美元，是继2018年达到6千亿美元后，时隔7年再创 新高。 今年上半年受不确定因素影响，韩国出口曾出现回落。但随着新政府上台后市场信心回稳，自6月 起出口开始强劲反弹，最终促成全年突破性增长。此外，截至今年9月，中小企业出口额与出口企业数 量均创历史新高。 ...

1月6日晚间，毛戈平化妆品股份有限公司（HK01318，以下简称毛戈平公司）发布减持公告。公告称， 股东系因自身财务需求拟减持其所持有的部分股份，减持所得款用途包括但限于美妆相关产业链的投 资、改善个人生活等。 果然财经|毛戈平与家人拟减持公司股份，将套现超10亿 大众报业·齐鲁壹点46分钟前 果然财经|毛戈平与家人拟减持公司股份，将套现超10亿 热门评论我要评论 微信扫码 移动端评论 暂无评论 鲁ICP备15022957号-13 鲁公网安备 37010202002220号 鲁新网备案号201000101 电信增值业务许可证： 鲁B2-20120085 齐鲁晚报·齐鲁壹点 版权所有(C) All Rights Reserved 联系电话：0531-82625462邮箱： 1790179766@qq.com ...

Group 1 - Kelong Pharmaceutical has seen a reduction in holdings by the China Europe Medical Health Mixed Fund managed by fund manager Ge Lan, from 42.60 million shares at the end of Q2 2025 to 38.20 million shares by the end of Q4 2025, indicating a decrease of 1.87 million shares [1] - The same fund had already begun reducing its stake in Kelong Pharmaceutical in Q3 2025, where the holdings decreased from 42.60 million shares to 40.06 million shares, a reduction of 2.53 million shares [1] - In contrast, the Industrial Bank of China Credit Suisse Frontier Medical Stock Fund managed by Zhao Bei increased its holdings in Kelong Pharmaceutical from 20.00 million shares at the end of Q3 2025 to 22.00 million shares by the end of Q4 2025 [1] Group 2 - Proya, another well-known consumer goods company, announced a share buyback on January 5, 2025, revealing that the Invesco Great Wall Emerging Growth Mixed Fund managed by Liu Yanchun reduced its holdings from 3.33 million shares at the end of Q3 2025 to 2.60 million shares by the end of December 30, 2025, a decrease of over 700,000 shares [2] - Additionally, the fund managed by Hu Xinwei, the Huatai-PineBridge Consumer Industry Mixed Fund, has exited the top ten circulating shareholders of Proya [2]